Literature DB >> 3210658

[Value of preoperative thrombocyte marking in patients with idiopathic thrombocytopenic purpura].

M Gietz1, W Mempel, C Clemm, E Hiller, M Heim, W Wilmanns.   

Abstract

51Cr-platelet kinetic studies were performed in 77 patients with idiopathic thrombocytopenic purpura. The sequestration site was splenic for 63, splenic/hepatic for 7 or hepatic for remaining 7 patients. In 20 patients platelet survival was extremely shortened to 0-3 h, whereas only 26 patients had a survival time of more than 24 h. Those patients with low platelet counts also had a very short platelet survival time, whereas patients with higher platelet counts (greater than 50 x 10(9)/l) had longer platelet survival times. 51 patients (66%) were splenectomized following the kinetic studies. 25 patients who had a splenic sequestration site had normalized platelet counts and 6 patients had platelet counts between 80-149 x 10(9)/l 12 months after splenectomy (i.e. in 92% of cases with splenic sequestration site a full or partial remission). Of the 11 patients with a hepatic or splenic/hepatic sequestration site, 2 patients had full remission, 1 partial remission, 3 patients had minimal improvement and 5 other patients were treatment failures in respect to the splenectomy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3210658     DOI: 10.1007/bf01728805

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  21 in total

1.  Results of treatment in 71 patients with idiopathic thrombocytopenic purpura.

Authors:  M C MEYERS
Journal:  Am J Med Sci       Date:  1961-09       Impact factor: 2.378

2.  Recommended methods for radioisotope platelet survival studies: by the panel on Diagnostic Application of Radioisotopes in Hematology, International Committee for Standardization in Hematology.

Authors: 
Journal:  Blood       Date:  1977-12       Impact factor: 22.113

3.  (51Cr)platelet kinetics in thrombocytopenia. Correlation between splenic sequestration of platelets and response to splenectomy.

Authors:  C A Ries; D C Price
Journal:  Ann Intern Med       Date:  1974-06       Impact factor: 25.391

4.  Cumulative experience in the detection of antiplatelet antibody in 234 patients with idiopathic thrombocytopenic purpura, systemic lupus erythematosus and other clinical disorders.

Authors:  S Karpatkin; N Strick; M B Karpatkin; G W Siskind
Journal:  Am J Med       Date:  1972-06       Impact factor: 4.965

Review 5.  Autoimmune thrombocytopenic purpura.

Authors:  S Karpatkin
Journal:  Blood       Date:  1980-09       Impact factor: 22.113

Review 6.  Autoimmune platelet destruction: idiopathic thrombocytopenic purpura.

Authors:  J G Kelton; S Gibbons
Journal:  Semin Thromb Hemost       Date:  1982-04       Impact factor: 4.180

7.  Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis.

Authors:  J Pizzuto; R Ambriz
Journal:  Blood       Date:  1984-12       Impact factor: 22.113

8.  The clinical significance of platelet-associated IgG: a study on 298 patients with various disorders.

Authors:  C Mueller-Eckhardt; W Kayser; K Mersch-Baumert; G Mueller-Eckhardt; M Breidenbach; H G Kugel; M Graubner
Journal:  Br J Haematol       Date:  1980-09       Impact factor: 6.998

9.  Influence of the amount of platelet-bound IgG on platelet survival and site of sequestration in autoimmune thrombocytopenia.

Authors:  L M Kernoff; K C Blake; D Shackleton
Journal:  Blood       Date:  1980-05       Impact factor: 22.113

10.  Danazol for the treatment of idiopathic thrombocytopenic purpura.

Authors:  Y S Ahn; W J Harrington; S R Simon; R Mylvaganam; L M Pall; A G So
Journal:  N Engl J Med       Date:  1983-06-09       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.